Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Sarcoma, Kaposi 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Leukemia, Prolymphocytic 1 Leukemia, Plasma Cell 1 Leukemia, Myeloid, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hematologic Diseases 1 Cholangiocarcinoma 1 Burkitt Lymphoma 1

Interventions

Gemcitabine 58 Cisplatin 32 Oxaliplatin 28 Fluorouracil 21 lenvatinib 20 durvalumab 18 Capecitabine 18 Leucovorin 15 tislelizumab 10 pembrolizumab 10 apatinib 9 Floxuridine 8 Specimen Handling 7 Panitumumab 7 Magnetic Resonance Spectroscopy 7 Albumin-Bound Paclitaxel 7 sintilimab 6 pemigatinib 6 S 1 (combination) 6 Radiotherapy 6 Irinotecan 6 Drug Therapy 6 Biopsy 6 tremelimumab 5 regorafenib 5 olaparib 5 camrelizumab 5 Taxes 5 Nivolumab 5 Folfox protocol 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Cholangiocarcinoma × Association × Clear all

NCT01912053 2018-05-11

MispheC

Center Eugene Marquis

Phase 2 Completed

Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡